Spots Global Cancer Trial Database for malignant neoplasm of breast
Every month we try and update this database with for malignant neoplasm of breast cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | NCT03435952 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Pembrolizumab Clostridium Nov... Doxycycline | 18 Years - | M.D. Anderson Cancer Center | |
| Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | NCT03463954 | Malignant Neopl... | Novilase Laser ... | 18 Years - | Novian Health Inc. | |
| ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes | NCT01395706 | Malignant Neopl... | ICG Fluorescenc... | 18 Years - 80 Years | Pulsion Medical Systems SE | |
| A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer | NCT02131506 | HER-2 Positive ... Malignant Neopl... | Lapatinib, Cael... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | NCT05364450 | Breast Neoplasm Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear | Enhanced Usual ... Acceptance Comm... Cognitive Behav... | 18 Years - 99 Years | Indiana University | |
| Breast Reconstruction Following Breast Cancer in Very High Risk Patients | NCT03261323 | Breast Cancer Malignant Neopl... | Immediate Breas... Delayed Breast ... Breast-Q questi... | 19 Years - | Case Comprehensive Cancer Center | |
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | NCT05033756 | Malignant Neopl... Breast Cancer | Pembrolizumab I... Olaparib Oral T... | 18 Years - | Institut fuer Frauengesundheit | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | NCT05364450 | Breast Neoplasm Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear | Enhanced Usual ... Acceptance Comm... Cognitive Behav... | 18 Years - 99 Years | Indiana University | |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | NCT03289819 | Malignant Neopl... | Pembrolizumab nab-paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | Institut fuer Frauengesundheit | |
| Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality | NCT02378337 | Malignant Neopl... Hodgkin Disease Non-Hodgkin Lym... Malignant Neopl... Malignant Neopl... Secondary Neopl... Malignant Melan... Malignant Neopl... | Image quantify | 18 Years - | Hospital Sao Rafael | |
| Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | NCT01953003 | Malignant Neopl... | vinflunine Capecitabine | 21 Years - 80 Years | Pierre Fabre Medicament | |
| Breast Reconstruction Following Breast Cancer in Very High Risk Patients | NCT03261323 | Breast Cancer Malignant Neopl... | Immediate Breas... Delayed Breast ... Breast-Q questi... | 19 Years - | Case Comprehensive Cancer Center | |
| Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | NCT05159778 | Malignant Neopl... | Imprime PGG Pembrolizumab | 18 Years - | HiberCell, Inc. | |
| Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery | NCT04669873 | Malignant Neopl... | Active Comparat... Experimental 1:... Experimental 2:... | 50 Years - 90 Years | Instituto Brasileiro de Controle do Cancer | |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | NCT03366428 | Malignant Neopl... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | NCT03379428 | Breast Neoplasm... Malignant Neopl... | Trastuzumab Ibrutinib 560 m... Ibrutinib 840 m... Ibrutinib 420 m... | 18 Years - | US Oncology Research | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment | NCT02891681 | Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Malignant Neopl... | Optical Tomogra... | 18 Years - | Washington University School of Medicine | |
| Breast Reconstruction Following Breast Cancer in Very High Risk Patients | NCT03261323 | Breast Cancer Malignant Neopl... | Immediate Breas... Delayed Breast ... Breast-Q questi... | 19 Years - | Case Comprehensive Cancer Center | |
| Swedish Ibrance Registries Insights (SIRI) | NCT04654208 | Malignant Neopl... | palbociclib | 18 Years - 99 Years | Pfizer | |
| MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery | NCT02408393 | Malignant Neopl... | Saline Ropivacaine | 18 Years - 85 Years | Institut Curie | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Therapeutic Dose Monitoring (TDM) of Tamoxifen | NCT05133674 | Breast Cancer Breast Carcinom... Breast Tumors Cancer of Breas... Malignant Neopl... | Tamoxifen 20 mg | 18 Years - | Karolinska University Hospital | |
| Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy | NCT02204098 | Breast Cancer Breast Carcinom... Malignant Neopl... | Mammaglobin-A D... Optional biopsy | 18 Years - | Washington University School of Medicine | |
| Low-field MRI for Breast Cancer Screening | NCT05486520 | Breast Benign Malignant Neopl... Breast Malignan... | Magnetic Resona... | 20 Years - 80 Years | Massachusetts General Hospital | |
| Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors | NCT05364450 | Breast Neoplasm Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear | Enhanced Usual ... Acceptance Comm... Cognitive Behav... | 18 Years - 99 Years | Indiana University | |
| Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | NCT01639911 | Malignant Neopl... CNS Malignancy Malignant Neopl... Genitourinary N... Head and Neck N... Melanoma Malignant Neopl... | Alisertib Pazopanib | 18 Years - | University of Illinois at Chicago | |
| Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | NCT02187991 | Breast Cancer Breast Carcinom... Breast Tumors Malignant Neopl... | Paclitaxel Alisertib | 18 Years - | US Oncology Research | |
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | NCT06251544 | Breast Cancer Tumor, Breast Breast Tumor Malignant Neopl... Mammary Cancer Mammary Neoplas... Mammary Neoplas... Neoplasm, Breas... | HTR2 T Cells HTR2 T Cells | 18 Years - 80 Years | Baylor College of Medicine | |
| A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer | NCT02131506 | HER-2 Positive ... Malignant Neopl... | Lapatinib, Cael... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Selumetinib and Olaparib in Solid Tumors | NCT03162627 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Selumetinib Olaparib | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | NCT03366428 | Malignant Neopl... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | NCT01953003 | Malignant Neopl... | vinflunine Capecitabine | 21 Years - 80 Years | Pierre Fabre Medicament | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors | NCT05067972 | Ovarian Neoplas... Endometrial Neo... Breast Neoplasm... | PF-07260437 B7-H4 IHC | 18 Years - | Pfizer | |
| Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment | NCT02891681 | Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Malignant Neopl... | Optical Tomogra... | 18 Years - | Washington University School of Medicine | |
| Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients | NCT02495363 | Malignant Neopl... | PECS Block Bupivacaine 0.2... | 18 Years - | Rabin Medical Center | |
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | NCT06251544 | Breast Cancer Tumor, Breast Breast Tumor Malignant Neopl... Mammary Cancer Mammary Neoplas... Mammary Neoplas... Neoplasm, Breas... | HTR2 T Cells HTR2 T Cells | 18 Years - 80 Years | Baylor College of Medicine | |
| Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors | NCT02611544 | Breast Neoplasm... Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear Neoplasm Remiss... Spontaneous Neo... Regression, Spo... Remission, Spon... Spontaneous Neo... | Acceptance and ... Survivorship Ed... Enhanced Usual ... | 18 Years - 99 Years | Indiana University | |
| Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | NCT03425656 | Malignant Neopl... | Trastuzumab plu... | 18 Years - 70 Years | AryoGen Pharmed Co. | |
| Low-field MRI for Breast Cancer Screening | NCT05486520 | Breast Benign Malignant Neopl... Breast Malignan... | Magnetic Resona... | 20 Years - 80 Years | Massachusetts General Hospital | |
| Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors | NCT02611544 | Breast Neoplasm... Breast Cancer Breast Carcinom... Malignant Neopl... Cancer of Breas... Mammary Neoplas... Human Mammary C... Malignant Tumor... Mammary Cancer Mammary Carcino... Anxiety Fear Neoplasm Remiss... Spontaneous Neo... Regression, Spo... Remission, Spon... Spontaneous Neo... | Acceptance and ... Survivorship Ed... Enhanced Usual ... | 18 Years - 99 Years | Indiana University | |
| An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer | NCT03429907 | Malignant Neopl... | Mind-Body Exerc... Questionnaires | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
